EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo

EFPIA and PhRMA issued a joint statement on November 21, stressing that they “regret” the Japanese government’s decision to implement a major out-of-cycle price reduction for Ono Pharmaceutical’s immuno-oncology drug Opdivo (nivolumab) next February. “EFPIA and PhRMA regret the continued...read more